# Everett Cunningham

Type: Person

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/everett-cunningham
Canonical HTML page: https://gethealthbrief.com/entity/everett-cunningham

## Timeline

- **2026-03-02**: Earnings Call — Management confirms CMS reimbursement rate of $897 and 2025 assay expansion.
- **2026-01-15**: FDA Submission — 510(k) premarket notification submitted for Lucent AD Complete.
- **2025-12-31**: Q4 2025 Close — Quanterix reports $43.9M in revenue with 25% YoY growth.

## Recent coverage (1 stories)

### Quanterix Secures CMS Reimbursement for Alzheimer’s Test Amid Q4 Growth
2026-03-04 00:20:22 · Sentiment: Positive · Impact: 6/10 · Sources: 6

Quanterix reported a 25% year-over-year revenue increase to $43.9 million in Q4 2025, driven by a surge in diagnostics partner revenue and critical regulatory milestones. The company achieved a commercial breakthrough with a $897 CMS reimbursement rate for its Lucent AD Complete test, positioning it for large-scale clinical adoption.
Full story: https://gethealthbrief.com/story/quanterix-q4-2025-alzheimers-diagnostics-milestone

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.